<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201470</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9891</org_study_id>
    <nct_id>NCT04201470</nct_id>
  </id_info>
  <brief_title>Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis</brief_title>
  <acronym>AMIS</acronym>
  <official_title>Serum Neurofilaments Light Chain and GFAP (Glial Fibrillary Acidic Protein) in Atypical Idiopathic Inflammatory Demyelinating Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic inflammatory disorders of the central nervous system include various disorders of&#xD;
      which multiple sclerosis is the most common. Besides multiple sclerosis, other distinct&#xD;
      disorders including for example anti-AQP4 (aquaporine-4) and anti-MOG (Myelin oligodendrocyte&#xD;
      glycoprotein) NMOSD (Neuromyelitis optica spectrum disorder) have been well characterized and&#xD;
      are now known to be distinct from MS.&#xD;
&#xD;
      some patient belonging to MS spectrum have recently being characterized but unusual MRI&#xD;
      findings have mimicking inherited leukoencephalopathies and leukodystrophies.&#xD;
&#xD;
      Whether these patients with atypical phenotype represent a separate disease distinct from MS&#xD;
      or belong to MS spectrum is not clear.&#xD;
&#xD;
      The objectives are to evaluate a series of 15 patients with atypical forms of MS using&#xD;
      non-conventional MRI techniques and biological biomarkers (serum neurofilaments light chain)&#xD;
      and to compare them with classical MS patients (15 relapsing remitting patients and 15&#xD;
      progressive patients) and 15 controls. the hypothesize is that these patients with atypical&#xD;
      MS have a more severe neurodegenerative process.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum neurofilaments light chain</measure>
    <time_frame>Between baseline (day 0) and day 60</time_frame>
    <description>Evaluation of serum neurofilaments light chain levels in patients with atypical MS and comparison with controls and patients with classical MS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum GFAP</measure>
    <time_frame>Between baseline (day 0) and day 60</time_frame>
    <description>Evaluation of serum GFAP levels in patients with atypical MS and comparison with controls and patients with classical MS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <condition>Progressive Multiple Sclerosis</condition>
  <condition>Controls</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with atypical MS identified in our cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Measurement of serum neurofilaments light chain and GFAP</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Cervical and cerebral MRI without contrast injection</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurologic / neuropsychologic tests - Patients</intervention_name>
    <description>EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)</description>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurologic / neuropsychologic tests - Controls</intervention_name>
    <description>NHPT, T25FW, CSCT</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must have given his informed consent and signed the consent form (if&#xD;
             patient is protected by the law due to the study pathology, the consent will be signed&#xD;
             his tutor or guardian ; if patient is unable to read or sign the consent form due to&#xD;
             the study pathology, the consent will be signed by his family/trusted person)&#xD;
&#xD;
          -  The subject is at least 18 years old (≥).&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Inclusion criteria specific to Patients:&#xD;
&#xD;
          -  Patients with atypical form of MS&#xD;
&#xD;
          -  OR patients with RRMS (Relapsing-Remitting Multiple Sclerosis)&#xD;
&#xD;
          -  OR patients with PPMS (Primary Progressive Multiple Sclerosis)&#xD;
&#xD;
        (Patients will be matched on EDSS score (+/-1) and age (+/-5) ; Controls will be matched&#xD;
        with patients on age)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Vulnerable people.&#xD;
&#xD;
          -  Simultaneous participation in any other research protocol.&#xD;
&#xD;
          -  Contraindication to the realization of an MRI (ferromagnetic ocular or cerebral&#xD;
             foreign bodies close to nerve structures, pace-maker, cochlear implants)&#xD;
&#xD;
          -  Claustrophobic subject&#xD;
&#xD;
          -  Subject presenting a neurodegenerative disease (Parkinson, Alzheimer ...)&#xD;
&#xD;
          -  Subject presenting psychiatric disorders like psychosis, excluding anxio-depressive&#xD;
             episode&#xD;
&#xD;
          -  Subject presenting a systemic pathology with neurological manifestation&#xD;
&#xD;
          -  Subject presenting anterior or evolutionary neurological pathology other than the 3&#xD;
             entities defined in the inclusion criteria&#xD;
&#xD;
          -  Subject presenting or having had a history of severe group 2 or 3 head trauma&#xD;
             according to the Masters classification&#xD;
&#xD;
          -  Patient receiving high dose corticosteroid therapy in the 3 months prior to inclusion&#xD;
             in the study&#xD;
&#xD;
        Exclusion criteria specific to Patients:&#xD;
&#xD;
          -  Patient who is taking, or who has taken in the last year, one of the following&#xD;
             treatments: Fingolimod, or any Monoclonal Antibody (Natalizumab, Rituximab,&#xD;
             Ocrelizumab, Alemtuzumab ...)&#xD;
&#xD;
          -  Patient having had an outbreak of the disease in the 3 months prior to inclusion in&#xD;
             the study&#xD;
&#xD;
        Exclusion criteria specific to Controls:&#xD;
&#xD;
          -  Subjects who are protected or unable to give their consent&#xD;
&#xD;
          -  Subject with anterior or progressive neurological pathology&#xD;
&#xD;
          -  Patient being treated or having taken any Monoclonal Antibody&#xD;
&#xD;
          -  In the period of exclusion relating to another protocol or for which the annual amount&#xD;
             of the maximum indemnities of 4500 € has been reached&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier Ayrignac, MD</last_name>
    <phone>+33687202393</phone>
    <email>x-ayrignac@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric Pinna</last_name>
    <phone>04 67 33 95 18</phone>
    <email>f-pinna@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Ayrignac, MD</last_name>
      <phone>+33687202393</phone>
      <email>x-ayrignac@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atypical multiple sclerosis</keyword>
  <keyword>Cavitary multiple sclerosis</keyword>
  <keyword>Myelocortical multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

